Ii Robert C. Goeltz Arcus Biosciences, Inc. (RCUS) insider trading activity

Ii Robert C. Goeltz is Chief Financial Officer of Arcus Biosciences, Inc.. Currently has a direct ownership of 91,924 shares of RCUS, which is worth approximately $1.84 Million. The most recent transaction as insider was on Jan 23, 2026, when has been sold 24,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 91.9K

0.23% 3M change

5.37% 12M change

Total Value Held $1.84 Million

II Robert C. Goeltz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 23 2026	BUY Grant, award, or other acquisition	-	24,000 Added 20.7%	91,924 Common Stock
Dec 31 2025	SELL Open market or private sale	$153,185 $23.38 p/Share	6,552 Reduced 8.8%	67,924 Common Stock
Dec 17 2025	SELL Open market or private sale	$132,073 $22.16 p/Share	5,960 Reduced 7.41%	74,476 Common Stock
Dec 16 2025	SELL Open market or private sale	$146,639 $21.88 p/Share	6,702 Reduced 7.69%	80,436 Common Stock
Nov 26 2025	SELL Open market or private sale	$125,000 $25.0 p/Share	5,000 Reduced 5.43%	87,138 Common Stock
Oct 28 2025	SELL Open market or private sale	$100,000 $20.0 p/Share	5,000 Reduced 5.15%	92,138 Common Stock
Jan 23 2025	BUY Grant, award, or other acquisition	-	37,000 Added 27.58%	97,138 Common Stock

Dec 31 2024	SELL Open market or private sale	$53,910 $15.0 p/Share	3,594 Reduced 5.64%	60,138 Common Stock
Dec 15 2024	SELL Payment of exercise price or tax liability	$162,391 $16.08 p/Share	10,099 Reduced 13.68%	63,732 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	21,300 Added 22.56%	73,131 Common Stock
Jan 02 2024	SELL Open market or private sale	$40,080 $20.0 p/Share	2,004 Reduced 3.72%	51,831 Common Stock
Dec 19 2023	SELL Sale (or disposition) back to the issuer	$50,796 $18.09 p/Share	2,808 Reduced 4.96%	53,835 Common Stock
Dec 18 2023	SELL Sale (or disposition) back to the issuer	$48,767 $17.74 p/Share	2,749 Reduced 4.63%	56,643 Common Stock
Jun 07 2023	SELL Open market or private sale	$81,141 $20.04 p/Share	4,049 Reduced 6.38%	59,392 Common Stock
Jan 23 2023	BUY Grant, award, or other acquisition	-	34,000 Added 34.89%	63,441 Common Stock
Dec 16 2022	SELL Open market or private sale	$75,920 $30.95 p/Share	2,453 Reduced 17.5%	11,566 Common Stock
Mar 08 2022	BUY Grant, award, or other acquisition	-	15,500 Added 40.77%	22,519 Common Stock
Dec 17 2021	SELL Open market or private sale	$24,908 $40.11 p/Share	621 Reduced 8.13%	7,019 Common Stock
Dec 16 2021	SELL Open market or private sale	$19,415 $40.03 p/Share	485 Reduced 5.97%	7,640 Common Stock
Jan 19 2021	BUY Grant, award, or other acquisition	-	12,500 Added 41.67%	17,500 Common Stock

IRC

Ii Robert C. Goeltz

Chief Financial Officer

Hayward, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RCUS shares.

Notify only if

Value

Insider Trading

Get notified when an Arcus Biosciences, Inc. insider buys or sells RCUS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Arcus Biosciences, Inc.

Track Activities on RCUS

Account